Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.

You may also be interested in...



NICE Rejects Novartis’ Afinitor, Citing Irrelevant Evidence And High Cost

NICE has rejected Novartis’ Afinitor for breast cancer, citing excessive cost and shooting down three out of four evidence submissions.

Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems

Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.

EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor

The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel